Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
About this item
Full title
Author / Creator
Seymour, John F , Kipps, Thomas J , Eichhorst, Barbara , Hillmen, Peter , D’Rozario, James , Assouline, Sarit , Owen, Carolyn , Gerecitano, John , Robak, Tadeusz , De la Serna, Javier , Jaeger, Ulrich , Cartron, Guillaume , Montillo, Marco , Humerickhouse, Rod , Punnoose, Elizabeth A , Li, Yan , Boyer, Michelle , Humphrey, Kathryn , Mobasher, Mehrdad and Kater, Arnon P
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In a trial involving patients with relapsed or refractory chronic lymphocytic leukemia, the BCL2 inhibitor venetoclax in combination with rituximab resulted in a higher 2-year rate of progression-free survival than bendamustine in combination with rituximab (85% vs. 36%).
Alternative Titles
Full title
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Authors, Artists and Contributors
Author / Creator
Kipps, Thomas J
Eichhorst, Barbara
Hillmen, Peter
D’Rozario, James
Assouline, Sarit
Owen, Carolyn
Gerecitano, John
Robak, Tadeusz
De la Serna, Javier
Jaeger, Ulrich
Cartron, Guillaume
Montillo, Marco
Humerickhouse, Rod
Punnoose, Elizabeth A
Li, Yan
Boyer, Michelle
Humphrey, Kathryn
Mobasher, Mehrdad
Kater, Arnon P
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_hal_primary_oai_HAL_hal_02348612v1
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_02348612v1
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1713976
